Episcleral Brachytherapy for the Treatment of Wet AMD
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, open-label, safety, usability and tolerability trial of
Strontium 90 (Sr90) beta radiation episcleral brachytherapy in subjects receiving aflibercept
therapy pro re nata (PRN) for the treatment of early neovascular Age-related Macular
Degeneration (nAMD) lesions. Secondary aims are to observe clinical outcomes of area of
leakage, sub-retinal fluid, lesion size, visual acuity, and anti-vascular endothelial growth
factor (anti-VEGF) treatment burden.